Search Result

Results for "

sst3

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Somatostatin Receptor (14) Urotensin Receptor (1)
By Research Areas:	Cancer (6) Cardiovascular Disease (1) Endocrinology (7) Inflammation/Immunology (1) Neurological Disease (6)

Inhibitors & Agonists

Peptides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P1203

BIM-23056	Somatostatin Receptor	Neurological Disease
BIM 23056, a linear octapeptide, is a potent *sst3* and *sst5* somatostatin receptor antagonist with K_i values of 10.8, 5.7, respectively .

HY-P1202

CYN 154806 1 Publications Verification	Somatostatin Receptor	Endocrinology
CYN 154806, a cyclic octapeptide, is a potent and selective *somatostatin sst2 receptor* antagonist, with pIC₅₀ values of 8.58, 5.41, 6.07, 5.76 and 6.48 for human recombinant sst2, sst1, sst3, sst4 and sst5 receptors respectively .

HY-P1202A

CYN 154806 TFA 1 Publications Verification	Somatostatin Receptor	Endocrinology
CYN 154806 TFA, a cyclic octapeptide, is a potent and selective somatostatin sst2 receptor antagonist, with pIC₅₀ values of 8.58, 5.41, 6.07, 5.76 and 6.48 for human recombinant sst2, sst1, sst3, sst4 and sst5 receptors respectively .

HY-P1206

CH 275	Somatostatin Receptor	Neurological Disease
CH 275 is a peptide analog of somatostatin and binds preferably to somatostatin receptor 1 (sst₁) with a K_i of 52 nM . CH 275 acts as a potent and selective sst₁ agonist (IC₅₀=30.9 nM) and also displays IC₅₀ values of 345 nM, >1 μM, >10 μM, >10 μM for human sst₃, sst₄, sst₂ and sst₅, respectively . CH 275 can be used for the research of alzheimer’s disease ^[3].

HY-79135

Pasireotide ditrifluoroacetate 5 Publications Verification SOM230 ditrifluoroacetate; Pasireotide TFA salt	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230) ditrifluoroacetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes *sst1/2/3/4/5, pK_i*=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide ditrifluoroacetate exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-79136

Pasireotide L-aspartate salt 5 Publications Verification SOM230 L-aspartate	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230) L-aspartate salt, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes *sst1/2/3/4/5, pK_i*=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide L-aspartate salt exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-16381

Pasireotide 5 Publications Verification SOM230	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230), a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes *sst1/2/3/4/5, pK_i*=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide also exhibits antisecretory, antiproliferative, and proapoptotic activity ^[3].

HY-P1203A

BIM-23056 TFA	Somatostatin Receptor	Neurological Disease
BIM 23056 TFA, a linear octapeptide, is a potent *sst3* and *sst5* somatostatin receptor antagonist with K_i values of 10.8, 5.7, respectively .

HY-P4469

PRL 3195	Somatostatin Receptor Urotensin Receptor	Cardiovascular Disease
PRL 3195 is a somatostatin receptor antagonist with K_is of 6, 17, 66, 1000 and 1000 nM for human somatostatin receptors (sst₅, sst₂, sst₃, sst₁ and sst₄, respectively) .

HY-108768

Pasireotide pamoate SOM230 pamoate	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230) pamoate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes *sst1/2/3/4/5, pK_i*=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide pamoate exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-16381A

Pasireotide acetate 5 Publications Verification SOM230 acetate	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230) acetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes *sst1/2/3/4/5, pK_i*=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide acetate can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide acetate also exhibits antisecretory, antiproliferative, and proapoptotic activity ^[3].

HY-16381B

Pasireotide (diaspartate) SOM230 (diaspartate)	Somatostatin Receptor	Neurological Disease Cancer
Pasireotide (SOM230) diaspartate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes *sst1/2/3/4/5, pK_i*=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide diaspartate exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-111615

J-2156	Somatostatin Receptor	Neurological Disease
J-2156 is a high potent, selective *somatostatin receptor type 4 (SST4 receptor)* agonist with IC₅₀s of 0.05 nM and 0.07 nM for human and rat SST4 receptors, respectively. J-2156 is used for the relief of mechanical allodynia and mechanical hyperalgesia in the ipsilateral hindpaws in rats .

HY-111615A

J-2156 TFA	Somatostatin Receptor	Neurological Disease Inflammation/Immunology
J-2156 TFA is a high potent, selective *somatostatin receptor type 4 (SST₄* receptor) agonist with IC₅₀*s of 0.05 nM and 0.07 nM for human and rat SST₄* receptors, respectively. J-2156 TFA has anti-inflammatory activity and it is used for the relief of mechanical allodynia and mechanical hyperalgesia in the ipsilateral hindpaws in rats .

Cat. No.	Product Name	Target	Research Area

HY-P1203

BIM-23056	Somatostatin Receptor	Neurological Disease
BIM 23056, a linear octapeptide, is a potent *sst3* and *sst5* somatostatin receptor antagonist with K_i values of 10.8, 5.7, respectively .

HY-P1202

CYN 154806 1 Publications Verification	Somatostatin Receptor	Endocrinology
CYN 154806, a cyclic octapeptide, is a potent and selective *somatostatin sst2 receptor* antagonist, with pIC₅₀ values of 8.58, 5.41, 6.07, 5.76 and 6.48 for human recombinant sst2, sst1, sst3, sst4 and sst5 receptors respectively .

HY-P1202A

CYN 154806 TFA 1 Publications Verification	Somatostatin Receptor	Endocrinology
CYN 154806 TFA, a cyclic octapeptide, is a potent and selective somatostatin sst2 receptor antagonist, with pIC₅₀ values of 8.58, 5.41, 6.07, 5.76 and 6.48 for human recombinant sst2, sst1, sst3, sst4 and sst5 receptors respectively .

HY-P1206

CH 275	Somatostatin Receptor	Neurological Disease
CH 275 is a peptide analog of somatostatin and binds preferably to somatostatin receptor 1 (sst₁) with a K_i of 52 nM . CH 275 acts as a potent and selective sst₁ agonist (IC₅₀=30.9 nM) and also displays IC₅₀ values of 345 nM, >1 μM, >10 μM, >10 μM for human sst₃, sst₄, sst₂ and sst₅, respectively . CH 275 can be used for the research of alzheimer’s disease ^[3].

HY-16381

Pasireotide 5 Publications Verification SOM230	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230), a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes *sst1/2/3/4/5, pK_i*=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide also exhibits antisecretory, antiproliferative, and proapoptotic activity ^[3].

HY-16381A

Pasireotide acetate 5 Publications Verification SOM230 acetate	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230) acetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes *sst1/2/3/4/5, pK_i*=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide acetate can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide acetate also exhibits antisecretory, antiproliferative, and proapoptotic activity ^[3].

HY-111615A

J-2156 TFA	Somatostatin Receptor	Neurological Disease Inflammation/Immunology
J-2156 TFA is a high potent, selective *somatostatin receptor type 4 (SST₄* receptor) agonist with IC₅₀*s of 0.05 nM and 0.07 nM for human and rat SST₄* receptors, respectively. J-2156 TFA has anti-inflammatory activity and it is used for the relief of mechanical allodynia and mechanical hyperalgesia in the ipsilateral hindpaws in rats .

HY-P1203A

BIM-23056 TFA	Somatostatin Receptor	Neurological Disease
BIM 23056 TFA, a linear octapeptide, is a potent *sst3* and *sst5* somatostatin receptor antagonist with K_i values of 10.8, 5.7, respectively .

HY-P4469

PRL 3195	Somatostatin Receptor Urotensin Receptor	Cardiovascular Disease
PRL 3195 is a somatostatin receptor antagonist with K_is of 6, 17, 66, 1000 and 1000 nM for human somatostatin receptors (sst₅, sst₂, sst₃, sst₁ and sst₄, respectively) .

HY-108768

Pasireotide pamoate SOM230 pamoate	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230) pamoate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes *sst1/2/3/4/5, pK_i*=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide pamoate exhibits antisecretory, antiproliferative, and proapoptotic activity .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.